Antigen-specific cancer immunotherapy involves the delivery of tumor-associated antigen to the host for the generation of tumor-specific immune responses and antitumor effects. We hypothesized that different delivery systems may influence the pattern of antigen-specific immune response and the outcome of antitumor effect. We therefore evaluated recombinant vaccinia virus and naked DNA for the generation of antigen-specific immune responses and antitumor effects. We previously found that recombinant vaccinia and naked DNA vaccines containing the chimeric Sig/E7/LAMP-1 gene were capable of controlling the growth of HPV-16 E7-expressing tumor cells (TC-1). In this study, we performed a head-to-head comparison of optimized delivery of Sig/E7/LAMP-1 vaccinia and DNA vaccines using doseescalating tumor challenge. At a dose of 1 × 10 6 TC-1 cells per mouse, Sig/E7/LAMP-1 DNA provided 100% protection against subcutaneous growth of tumors, while VacSig/E7/LAMP-1 protected only 40% of the mice. Furthermore, Sig/E7/LAMP-1 DNA vaccines are capable of protect-
Introduction
The development of cancer vaccines has continued to show progress in recent years. 1 Immunotherapy has been shown to successfully control tumor growth in many murine tumor model systems. In addition, several phase I/II clinical trials using these vaccine strategies have yielded encouraging results in patients (for review, see Ref.
2). Tumor-specific antigens, when efficiently presented by antigen-presenting cells (APCs) to CD8 + cytotoxic T lymphocytes (CTLs) and CD4 + helper T (Th) cells, are capable of inducing potent T cell-mediated immunity -the most crucial component of antitumor immunity. The field of cancer immunotherapy is therefore moving towards the development of antigen-specific cancer vaccines, particularly those which enhance both ing against challenge with a more stringent subclone of TC-1 (TC-1 P2) established from TC-1 tumors that survived initial Sig/E7/LAMP-1 vaccinia vaccination. Immunological assays revealed that both vaccines induced comparable levels of CD8 + T cell precursors and anti-E7 antibody titers. Interestingly, Sig/E7/LAMP-1 vaccinia induced both E7-specific IFN-␥-and IL4-secreting CD4 + T cell precursors while Sig/E7/LAMP-1 DNA induced only E7-specific IFN-␥-secreting CD4
+ T cell precursors. We also found that IL-4 knockout C57BL/6 mice vaccinated with Sig/E7/LAMP-1 vaccinia exhibited a more potent antitumor effect than vaccinated wild-type C57BL/6 mice in our tumor protection experiments. These results suggest that IL-4 may play a detrimental role in the antitumor effect mediated by vaccinia vaccines. Our findings suggested that DNA vaccines may provide better tumor protection than vaccinia vaccines employing the same gene, which may have implications in the future design of antigen-specific cancer immunotherapy. Gene Therapy (2001) 8, 128-138.
CD4
+ and CD8 + T cell-mediated immune responses against tumors.
In an attempt to enhance antigen presentation to CD4 + T cells, we have previously linked the sorting signals of the lysosome-associated membrane protein-1 (LAMP-1) to the human papillomavirus-16 (HPV-16) E7 antigen, creating the Sig/E7/LAMP-1 chimera. This specific linkage led to the targeting of HPV-16 E7 to the endosomal and lysosomal compartments and enhanced MHC class II presentation of E7 to CD4 + T cells. 3 Furthermore, we demonstrated that this strategy was not only capable of activating CD4
+ T helper cells, it also led to enhancement of E7-specific CD8 + cytotoxic T cell activity. The LAMP-1 targeting strategy was further investigated in vivo using vaccinia in an E7-expressing tumor model, TC-1. Our results indicated that intraperitoneal vaccination of Sig/E7/LAMP-1-containing recombinant vaccinia virus (Vac-Sig/E7/LAMP-1) can generate strong antitumor immunity against TC-1 inoculated subcutaneously. 4 Subsequently, we have tested the VacSig/E7/LAMP-1 vaccine in a liver tumor 5 and lung metastasis model. 6 Our results indicated that this vaccine was capable of preventing and treating E7-expressing tumors.
More recently, we have extended the LAMP-1 targeting strategy to naked DNA vaccines. We found that the Sig/E7/LAMP-1 DNA vaccine administered via gene gun provided potent protection against the subcutaneous growth of TC-1 cells and eradicated established TC-1 tumors. 6 We also demonstrated a similarly potent antitumor immunity against TC-1 tumor metastases in the liver and lungs. 5 Since different vector delivery systems may influence the pattern of antigen-specific immune response and the outcome of antitumor effect, it is important to discover which of these systems may lead to the best antitumor effect. While vaccinia vaccines have the advantage of efficient delivery of genes of interest to target cells, repeat vaccination with this delivery system may be inhibited due to antibodies generated against vaccinia or other tolerance effects. On the other hand, DNA vaccines are safe, can be repeatedly administered, and can be expressed over an extended period of time to enhance immunologic memory. The concern about DNA vaccines is their limited potency, an issue which has been addressed using the Sig/E7/LAMP-1 strategy. To determine if the choice of vector delivery system for vaccination may influence vaccine potency, we performed a head-to-head comparison of different vector delivery systems (naked DNA versus vaccinia) containing the same gene (Sig/E7/LAMP-1) for their ability to generate E7-specific immune responses and antitumor immunity against dose-escalating challenge with TC-1 tumor cells and also against challenge using a more stringent tumor model, TC-1 P2.
Results
Vaccination with Sig/E7/LAMP-1 DNA generates a stronger antitumor effect compared with vaccination with Sig/E7/LAMP-1 vaccinia We have previously demonstrated that Sig/E7/LAMP-1 vaccinia can generate a potent antitumor effect against a tumor challenge of 5 × 10 4 TC-1 cells per mouse. 4 In addition, we have demonstrated that Sig/E7/LAMP-1 DNA is also capable of generating a potent antitumor effect against a tumor challenge of 5 × 10 4 TC-1 cells per mouse. 5, 6 In order to conduct a head-to-head comparison of Sig/E7/LAMP-1 DNA and Vac-Sig/E7/LAMP-1, it was necessary to first optimize the dose and vaccination regimen for each vaccine individually. We previously determined that a single vaccination with 1 × 10 7 p.f.u. per mouse Vac-Sig/E7/LAMP-1 generated the optimum antitumor effect. 4 Furthermore, we found that single vaccination with Sig/E7/LAMP-1 vaccinia generated better E7-specific CD8 + T cell immune response than a primebooster regimen of Sig/E7/LAMP-1 vaccinia. 7 In recent studies with the Sig/E7/LAMP-1 naked DNA vaccine, we found that prime and booster of 2 g DNA generated the optimum antitumor effect. 5, 6 We also found that vaccination with Sig/E7/LAMP-1 DNA was more effective with a prime-booster regimen than with a single-shot. 7 We therefore used these optimized vaccination regimens for our head-to-head comparison. We vaccinated mice with either Sig/E7/LAMP-1 DNA or VacSig/E7/LAMP-1 as described in Materials and methods. One week after vaccination, mice were challenged with 5 × 10 4 TC-1 cells per mouse subcutaneously in the right leg. As shown in Figure 1a , all of the unvaccinated conGene Therapy trol mice grew tumors within 3 weeks, whereas all of the mice vaccinated with either Sig/E7/LAMP-1 DNA or Vac-Sig/E7/LAMP-1 remained tumor free 6 weeks after tumor challenge. In comparison, when mice were challenged with 2 × 10 5 TC-1 cells per mouse subcutaneously in the right leg, Sig/E7/LAMP-1 DNA generated 100% tumor protection for up to 55 days while VacSig/E7/LAMP-1 generated 80% tumor protection after 10 days, falling to 60% after 21 days (Figure 1b) . When the challenged tumor dose was increased to 1 × 10 6 TC-1 cells per mouse, Sig/E7/LAMP-1 DNA still provided 100% tumor protection against the subcutaneous growth of TC-1 tumor. In contrast, Sig/E7/LAMP-1 vaccinia vaccines could provide tumor protection in only 40% of the mice after 10 days (Figure 1c ). These results indicated that Sig/E7/LAMP-1 DNA generated a more potent antitumor effect against TC-1 compared with VacSig/E7/LAMP-1 in our tumor protection experiments.
Vaccination with either Sig/E7/LAMP-1 DNA or VacSig/E7/LAMP-1 and their therapeutic potential to eradicate established E7-expressing tumors in the lungs To determine the therapeutic potential of Sig/E7/LAMP-1 DNA or Vac-Sig/E7/LAMP-1 in treating TC-1 tumor metastases in the liver, mice were first challenged with 1 × 10 4 TC-1 per mouse via intravenous tail vein injection. Three days later, mice were vaccinated as described in Materials and methods. Mice were killed 28 days after tumor challenge. We determined that Sig/E7/LAMP-1 DNA and Vac-Sig/E7/LAMP-1 exhibited a significantly higher therapeutic effect compared with no treatment as assessed by counting the mean number of pulmonary nodules ( Figure 2 ). Sig/E7/LAMP-1 DNA generated a slightly greater therapeutic effect compared with VacSig/E7/LAMP-1, although this difference was not statistically significant. These results indicated that both Sig/E7/LAMP-1 DNA and Vac-Sig/E7/LAMP-1 can generate potent antitumor treatment in the lung metastasis model using TC-1 tumor cells.
Vaccination with Sig/E7/LAMP-1 DNA generates stronger protection against a more stringent tumor model Our previous immunotherapy studies demonstrated that Vac-Sig/E7/LAMP-1 can effectively prevent and treat HPV-16 E7-expressing tumors (TC-1) in most cases. However, there is sporadic failure of this vaccine in up to 20% of incidents. 4 Thus, we developed an experimental system to enrich and isolate TC-1 tumor cells that can evade immunotherapy with Vac-Sig/E7/LAMP-1, which can then be used to compare several features of such immunoresistant TC-1 cells with parental cells. As shown in Figure 3 , we challenged E7-expressing TC-1 cells into VacSig/E7/LAMP-1 vaccinated mice, and selected the immunoresistant variant that established tumors in these mice. This variant was isolated and then rechallenged into Vac-Sig/E7/LAMP-1 vaccinated mice and the immunoresistant tumor cells were selected. After two cycles of the same procedure, the isolated TC-1 variant was designated as TC-1 P2 and represents a more stringent tumor model.
Since down-regulation of MHC class I molecules or loss of E7 expression may influence the susceptibility of TC-1 P2 to killing by E7-specific T cells, we examined MHC class I expression level using flow cytometry analy-sis and E7 expression level using Western blot analysis, comparing TC-1 P2 cells with TC-1 cells. As shown in Figure 4a , the level of MHC class I expression was similar for TC-1 P2 cells and original TC-1 cells. To determine the expression level of HPV-16 E7 in TC-1 P2 and original TC-1 cells, we performed a Western blot analysis and found that the expression level of E7 protein in TC-1 P2 was similar to that of the parent TC-1 ( Figure 4b ). These results indicated that the TC-1 P2 cells did not downregulate the MHC-I molecule or lose expression of E7.
To determine whether Sig/E7/LAMP-1 DNA could generate antitumor immunity against TC-1 P2 tumor cells, C57BL/6 mice were vaccinated with Sig/E7/LAMP-1 DNA via gene gun. Mice receiving VacSig/E7/LAMP-1 or no vaccination were used as controls. The mice were then challenged with 5 × 10 4 TC-1 P2 cells per mouse subcutaneously in the right leg. As shown in Figure 5 , Sig/E7/LAMP-1 DNA vaccines generated 60% tumor protection up to 3 months. Although VacSig/E7/LAMP-1 generated 33.3% tumor protection after 1 month, the tumor protection rate fell to 6.7% after 3 months. In contrast, all the unvaccinated mice grew tumors after 3 weeks. These data indicated that the Sig/E7/LAMP-1 DNA vaccine is capable of generating antitumor effects against TC-1 P2 tumor cells that are resistant to Vac-Sig/E7/LAMP-1 vaccine. + T cells. 8 As shown in Figure 6a , IFN-␥-secreting spot-forming cells observed in mice vaccinated with VacSig/E7/LAMP-1 (around 80/10 6 splenocytes) appear to be slightly higher than in mice vaccinated with Sig/E7/LAMP-1 DNA (around 60/10 6 splenocytes), although this difference is not statistically significant. The control (unvaccinated mice) and assays without E7 peptide demonstrated minimal background spots (Ͻ5/10 6 splenocytes). Similarly, E7-specific CD8 + T cell precursors can also be determined by flow cytometry analysis using double staining for CD8 and intracellular IFN-␥. As shown in Figure 6b using flow cytometry analysis, mice vaccinated with Vac-Sig/E7/LAMP-1 generated similar numbers of E7-specific CD8 + T cell precursors (around 273/10 6 splenocytes) compared with those obtained from mice vaccinated with Sig/E7/LAMP-1 DNA. Analysis of control mice (unvaccinated) did not reveal a significant number of E7-specific CD8 + T cell precursors. These results are consistent with data obtained in previous studies using CTL assays, demonstrating that VacSig/E7/LAMP-1 generated CTL activity comparable to Sig/E7/LAMP-1 DNA. 3, 5 Vaccination with Sig/E7/LAMP-1 DNA or Vac-Sig/E7/ LAMP-1 generates comparable anti-E7 antibody titers The anti-HPV-16 E7 antibodies in the sera of vaccinated mice were determined by a direct enzyme-linked immuGene Therapy
Figure 4 Characterization of MHC class I and E7 expression in TC-1 P2 cells. (a) Flow cytometry analysis to demonstrate the relative expression of MHC class I molecules on TC-1 P2 and parental TC-1 cells. Note: the expression level of MHC-I molecules on TC-1 P2 cells was similar to that on parental TC-1. (b) Western blot analysis to demonstrate the relative expression of E7 protein in TC-1 P2 cells and parental TC-1 cells. Note: the E7 protein was detected in both TC-1 P2 and parental TC-1 cells, but not in the control dendritic cells (DC). The expression level of E7 protein was even higher in TC-1 P2 than in parental TC-1.
noabsorbent assay (ELISA) 2 weeks after the last vaccination. The anti-HPV 16 E7 antibodies could be detected in the sera of both Vac-Sig/E7/LAMP-1 and Sig/E7/LAMP-1 DNA vaccinated mice. No significant difference in E7 antibody titers was noted between these two groups ( Figure 7) . We also determined the isotype of E7-specific antibodies in the sera from these vaccinated mice. An IgG1 predominance was seen in Sig/E7/LAMP-1 DNA vaccinated mice, suggesting a Th2 response. In contrast, a mixed IgG1/IgG2a profile was seen in VacSig/E7/LAMP-1 vaccinated mice, suggesting both a Th1 and Th2 response (data not shown). The combination of these tests demonstrated that while Vac-Sig/E7/LAMP-1 immunization generated comparable CD8
+ E7-specific cellular immune responses and IFN-␥-secreting CD4 + T cell response as Sig/E7/LAMP-1 DNA, Vac-Sig/E7/LAMP-1 generated a greater IL-4-secreting CD4
+ T cell response than Sig/E7/LAMP-1 DNA. These results indicated that vaccination with VacSig/E7/LAMP-1 generates higher Th2 type CD4 + T cell responses.
IL-4 knockout mice vaccinated with Vac-Sig/E7/LAMP-1 generated a stronger antitumor effect than C57BL/6 mice vaccinated with Vac-Sig/E7/LAMP-1 In our results, we have observed that C57BL/6 mice vaccinated with Sig/E7/LAMP-1 DNA generated a better antitumor effect than C57BL/6 mice vaccinated with VacSig/E7/LAMP-1 (Figure 1) . Furthermore, C57BL/6 mice vaccinated with Vac-Sig/E7/LAMP-1 generated higher levels of E7-specific IL-4-secreting CD4 + T cells ( Figure  8 ). To investigate the potential relationship between IL-4 secretion and the antitumor effect generated by these vaccines, we performed a tumor protection experiment using IL-4 knockout mice. IL-4 knockout mice were vaccinated with Sig/E7/LAMP-1 DNA, Vac-Sig/E7/LAMP-1, or were unvaccinated as described in Materials and methods. One week after the last vaccination, mice were challenged with 1 × 10 6 TC-1 cells per mouse. As shown in Figure 9 , 100% of IL-4 knockout mice mice vaccinated with either Sig/E7/LAMP-1 DNA or vaccinia remained tumor free up to 40 days after tumor challenge. In comparison, Sig/E7/LAMP-1 vaccinia could provide tumor protection in only 40% of the C57BL/6 mice after 10 days (Figure 1c) . These results indicated that IL-4 knockout C57BL/6 mice vaccinated with Sig/E7/LAMP-1 vaccinia exhibited a more potent antitumor effect than vaccinated wild-type C57BL/6 mice in our tumor protection experiments.
Discussion
Our results demonstrated that the Sig/E7/LAMP-1 DNA vaccine can generate antitumor immunity against a high dose of TC-1 tumor cells and against TC-1 P2 tumor cells that were resistant to the Vac-Sig/E7/LAMP-1 vaccine. Vac-Sig/E7/LAMP-1 generated E7-specific CD8 + T cell activity, CD4
+ IFN-␥ + T cell activity, and antibody activity comparable to that in Sig/E7/LAMP-1 DNA. However, the vaccinia vaccine also generated CD4
+ IL-4 + T cell precursors and did not generate significant antitumor immunity against TC-1 P2 tumor cells. These data demonstrated that vaccines containing the same gene but 
cell-mediated immune responses using ELISPOT and intracellular cytokine staining with flow cytometry analysis. C57BL/6 mice were immunized with Sig/E7/LAMP-1 DNA or Vac-Sig/E7/LAMP-1 vaccines. Splenocytes were harvested 12 days after vaccination. (a) The number of IFN-␥-producing E7-specific CD8 + T cell precursors was determined using the ELISPOT assay (see text for the detailed method). The spot numbers were the mean of triplicates ± s.e. in each vaccinated group. Mice vaccinated with Vac-Sig/E7/LAMP-1 generated higher IFN-␥ + spot numbers. Unvaccinated mice were used as a control. Furthermore, ELISPOT assays performed without E7 peptide were also used as a control. Results shown here are E7-specific spot numbers (subtracting the spot numbers without adding the E7 CTL peptide). (b) Splenocytes were cultured in vitro with E7 peptide (aa 49-57) overnight and stained for both CD8 and intracellular IFN-␥. The number of IFN-␥ secreting CD8 + T cell precursors was analyzed by flow cytometry. Mice vaccinated with Vac-Sig/E7/LAMP-1 generated higher IFN-␥-secreting E7-specific CD8
+ T cells. We observed that Vac-Sig/E7/LAMP-1 generated a greater E7-specific IL-4-secreting CD4 + T cell response compared with Sig/E7/LAMP-1 DNA.
VacSig/E7/LAMP-1 also generated an E7-specific IFN-␥-secreting CD4 + T cell response comparable to that of Sig/E7/LAMP-1 DNA. A higher IL-4 response may have a negative influence on the antitumor immunity of VacSig/E7/LAMP-1 because IL-4 produced by Th2 cells may suppress the generation of Th1 cells, 10 which are important in supporting the activation of CTL. 11 Our in vivo tumor protection experiment using IL-4 knockout mice was consistent with this notion (Figure 9 ). Previous studies, however, have diverged as to the true effect of IL-4 on antitumor immune responses. Fu et al 12 showed that IL-4 could suppress the antitumor effect of T cells, while Hung et al 13 showed that the antitumor immunity of cytokine-modified cancer cell vaccines was partially lost in IL-4 knockout mice. Schuler et al 14 It is also interesting to note that our flow cytometry analysis revealed a substantial population of IL-4-secreting, CD4-negative cells in the splenocytes of mice vaccinated with Vac-Sig/E7/LAMP-1. There are a variety of possible explanations for the expansion of such cells following vaccination with Vac-Sig/E7/LAMP-1. One possibility is that these CD4-/IL4 + cells are ␥␦ T cells. It has been suggested that ␥␦ T cells are involved in establishing primary immune responses. 15 Previous studies have shown that ␥␦ T cells discriminate between different pathogens early in infection by producing cytokines associated with the appropriate T-helper response. For example, T cells bearing ␥␦ receptors from mice infected with Nippostrongylus brasiliensis have been shown to produce IL-4. 15 Another possibility is that these CD4-/IL4
− NKT cells, a subset of IL-4 producing NKT cells. 16 The presence of NKT cells has been postulated to support both Th1 and Th2 cell responses and affect the development of antigen-specific T-regulatory cells involved in peripheral tolerance. 17 Further investigation of IL-4-secreting CD4 − splenocytes will facilitate the understanding of the mechanism of the antitumor effect generated by Vac-Sig/E7/LAMP-1.
Our results indicated that there was no significant difference in the number of E7-specific CD8 + T cell precursors generated by vaccination with Sig/E7/LAMP-1 DNA or Vac-Sig/E7/LAMP-1. Although our assays detected similar numbers of E7-specific CD8 + T cells for both vaccines, there may be limitations in our assays for determining the actual quantity and quality of active E7-specific CD8 + T cells. It has been shown that vaccinia vaccines may interfere with the presentation of some CTL epitopes of certain antigens. 18 It is therefore possible that CTLs generated by Sig/E7/LAMP-1 DNA were more heterogeneous, reactive to not only the dominant E7 epitope (aa 49-57) 19 but also to various other E7 CTL epitopes. Consequently, using the E7 (aa 49-57) peptide to define E7-specific cellular immunity in the CTL assay and ELISPOT assay may underestimate the actual E7-specific CD8 + cellular immune responses generated by the Sig/E7/LAMP-1 DNA vaccine. Furthermore, if TC-1 P2 selectively lost presentation of the E7 (aa 49-57) epitope but retained the ability to present other E7 CTL epitopes, we would also observe a significant difference in the antitumor effect generated by the Sig/E7/LAMP-1 DNA vaccine versus the Vac-Sig/E7/LAMP-1 vaccine. A loss of CTL epitope presentation may also be caused by single amino acid substitution due to point mutations within the sequences encoding the CTL recognition epitopes. 20 We sequenced the E7 gene in TC-1 P2 cells, but found no such mutations (data not shown).
Another potential difference between these vaccines is the quality of CTLs. In particular, the avidity of CTLs generated by Sig/E7/LAMP-1 DNA may be different from that generated by Vac-Sig/E7/LAMP-1. It has been shown that CTLs cultured with exceedingly low-dose peptide generated high-avidity CTLs. In contrast, a higher concentration of peptides generated low-avidity CTLs. Alexander-Miller et al 21 demonstrated that highavidity CTLs are much more effective at viral clearance than low-avidity CTLs, despite the fact that both highavidity and low-avidity CTLs can lyse virus-infected targets in vitro. This indicates that the in vitro CTL assay does not necessarily reflect the ability of in vivo viral clearance. This knowledge indicates that although Sig/E7/LAMP-1 DNA and Vac-Sig/E7/LAMP-1 generated comparable in vitro CD8 + T cell-mediated immune responses, the effectiveness of T cell responses may vary because the CTLs generated by each vaccine may possess varying degrees of avidity.
The different route of administration for Sig/E7/LAMP-1 DNA and Vac-Sig/E7/LAMP-1 vaccines may have influenced the induction of different immune responses. In genetic immunization, it has been suggested that gene gun-mediated DNA vaccination elicits Th2 responses. In contrast, intramuscular injection typically elicits Th1 responses. However, Barry et al 22 showed that increasing the amount of plasmid delivered via gene gun can shift the Th2 response to Th1. In addition, vaccinia administered though different routes of administration have been shown to generate different types of immune responses in a herpes simplex virus model. 23 Therefore, the difference in antitumor immunity and T helper responses generated by Sig/E7/LAMP-1 DNA and Vac-Sig/E7/LAMP-1 vaccines may be due to the combined effects of different antigen doses and different routes of administration. It is interesting to note that the immune response generated by Sig/E7/LAMP-1 DNA was Th1-like, according to the intracellular cytokine staining (IFN-␥ predominance). In contrast, the response was Th2-like according to the antibody isotype (IgG1 predominance). This discrepancy needs further characterization.
The differential effects of Sig/E7/LAMP-1 DNA versus Vac-Sig/E7/LAMP-1 on TC-1 P2 tumor cells may be due to differences in the activity of immune effectors other than CD4
+ and CD8 + T cells. Hung et al 13 demonstrated that both eosinophils and macrophages collaborate within the site of tumor challenge to cause tumor cell destruction via the production of both superoxide and nitric oxide. It would be interesting to discover whether such effectors were involved in the antitumor immunity generated by Vac-Sig/E7/LAMP-1 or Sig/E7/LAMP-1 DNA. Another immune effector type is the natural killer (NK) cell. The CpG motif in plasmid DNA has an immunostimulatory effect, possibly causing maturation of dendritic cells, 24 inducing Th1 responses 25 and NK cell lytic activity. 26 NK cells can kill MHC-I-negative tumor cells. 27 However, TC-1 P2 cells did not lose MHC class I expression, so the potential role of NK cells in mice vaccinated with Sig/E7/LAMP-1 DNA still remains to be determined.
In this study, we observed no loss of MHC class I expression or E7 expression in TC-1 P2 tumor cells. One possible mechanism for escape of TC-1 P2 cells from immune effector cells is the mutation of E7. We therefore sequenced PCR-amplified E7 protein and did not find any mutations (data not shown). Other potential mechanisms include expression of Fas ligand, 28 loss of TAP-1, 29, 30 decreased expression of some adhesion molecules, 31 Gene Therapy and/or secretion of some immunosuppressive substances. 32 Further studies will help elucidate whether such characteristics are responsible for the immune evasion exhibited by TC-1 P2 cells.
In summary, our results indicated that DNA vaccines containing Sig/E7/LAMP-1 generate better tumor pro- tection than vaccinia vaccines containing the same construct, even using a more stringent tumor model. The discrepancy in the antitumor effect observed between VacSig/E7/LAMP-1 and Sig/E7/LAMP-1 DNA may be attributed to higher IL-4 cytokine production (leading to Th1 suppression), or other possibilities, such as limited recognition of different CTL epitopes, production of CTLs with differing degrees of avidity, and varying production of other immune effector cells against TC-1 P2. The efficacy of antitumor immunity generated by active vaccination is probably influenced by an interaction between the immune effectors and tumor cells that involves some combination of the mechanisms proposed in this study. Continued investigation of these mechanisms will facilitate the design of better antigen-specific cancer immunotherapy in the future.
Materials and methods
Murine tumor cell lines TC-1: The production and maintenance of TC-1 cells has been described previously. 4 In brief, HPV-16 E6, E7 and ras oncogene were used to transform primary C57BL/6 mice lung epithelial cells. This tumorigenic cell line was named TC-1. 
Western blot analysis of E7 protein in tumor samples
Proteins were extracted from TC-1 or TC-1 P2 cells with M-PERTM Mammalian Protein Extraction Reagent (Pierce, Rockford, IL, USA). The protein concentration was determined by BSA assay (Bio-Rad, Hercules, CA, USA). Fifty g protein was separated on 4-20% linear gradient Precast Tris-HCl protein gel (Life Technology, Rockville, MD, USA) and then transferred on to nitrocellulose membrane (Bio-Rad). After blocking, the membrane was hybridized with 1:1000 diluted anti-E7 monoclonal antibody (Zymed, San Francisco, CA, USA). Antibody binding was detected using a peroxidase-conjugated sheep anti-mouse secondary antibody (Amersham, Piscataway, NJ, USA) and chemilluminescence (ECL + detection kit; Amersham).
Preparation of Vac-Sig/E7/LAMP-1 and Sig/E7/LAMP-1 DNA constructs A large batch of viral stock of Vac-Sig/E7/LAMP-1 was generated as described previously. 3 These viral stocks, after being proven to be able to generate antitumor immunity against TC-1, 4 were preserved at −70°C before vaccination. The preparation of Sig/E7/LAMP-1 DNA vaccine has also been described previously. 5, 6 Mice Six-to 8-week-old female C57BL/6 mice from the National Cancer Institute (Frederick, MD, USA) were purchased and kept in the oncology animal facility of the Johns Hopkins Hospital (Baltimore, MD, USA). C57BL/6 IL-4 knockout mice were kindly provided by Dr Ephraim Fuchs at the Johns Hopkins University. All animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
Vaccination
Previous studies in our laboratory have demonstrated that gene gun immunization of DNA vaccines is the most effective route of administration for the control of tumors (Wu, personal communication) . Our studies have also indicated that intraperitoneal vaccination is the most effective route of administration for vaccinia vaccines.
For Vac-Sig/E7/LAMP-1 vaccination, the virus was thawed, sonicated in liquid phase for 30 s, trypsinized with trypsin/EDTA in 37°C water bath for 30 min, and diluted with minimal essential medium containing 2.5% fetal bovine serum to the final concentration of 1 × 10 8 p.f.u./ml. Each mouse was vaccinated with 10 7 p.f.u. of Vac-Sig/E7/LAMP-1 (0.1 ml of the diluted vaccine) intraperitoneally.
For DNA vaccination, gene gun-mediated DNA vaccination was performed using a helium-driven gene gun (Bio-Rad) according to the protocol provided by the manufacturer as described previously. 5, 6 C57BL/6 mice were immunized with 2 g Sig/E7/LAMP-1 via gene gun and then boosted 1 week later with the same regimen as the first vaccination.
In vivo tumor protection experiments C57BL/6 mice and IL-4 knockout mice were vaccinated with Sig/E7/LAMP-1 DNA or Vac-Sig/E7/LAMP-1 as described above. One week after vaccination, C57BL/6 mice were challenged with TC-1 or TC-1 P2 tumor cells at a range of doses (5 × 10 4 , 2 × 10 5 , or 1 × 10 6 cells per mouse) and IL-4 knockout mice were challenged with TC-1 at 1 × 10 6 cells per mouse) by subcutaneous injection in the right leg. In addition, unvaccinated mice received the same amount of TC-1 or TC-1 P2 cells for natural tumor growth control. Tumor growth was monitored by visual inspection and palpation twice weekly.
In vivo tumor regression experiments
Preparation of tumor cells and DNA and vaccinia vaccines was performed as described above. The mice were challenged with TC-1 tumor cells first: 1 × 10 4 TC-1 cells per mouse for the lung metastasis model 5, 33 (five mice per group) intravenously in the tail vein. Three days after challenge with TC-1 tumor cells, mice were vaccinated with Sig/E7/LAMP-1 DNA (2 g per mouse) or VacSig/E7/LAMP-1 (1 × 10 7 p.f.u. per mouse). One week later, the mice receiving DNA were boosted with the same regimen as the first vaccination. Mice were monitored twice a week and were killed at day 28 after tumor challenge. Lungs were removed after mice were killed. The pulmonary metastatic nodules were counted under dissecting microscope. All pulmonary specimens without gross visible tumors were then fixed with 10% neutral buffered formalin, embedded in paraffin and cut into 5 m sections from different levels. After hematoxylin and eosin staining, the slides were examined using a conventional microscope.
ELISPOT assay
In brief, 96-well filtration plates (Millipore, Bedford, MA, USA) were coated with rat anti-mouse IFN-␥ antibody (PharMingen). Fresh isolated spleen cells from each vaccinated mice were added to each well with or without 1 g/ml E7 aa 49-57 MHC-I peptide 19 and incubated at 37°C for 24 h. After culture, the plate was incubated with biotinylated IFN-␥ antibody (PharMingen). The spots Gene Therapy were developed by adding streptavidin-alkaline phosphatase (Jackson ImmunoResearch, West Grove, PA, USA) and BCIP/NBT solution (Boehringer Mannheim, Indianapolis, IN, USA). The spot numbers were counted by computer-assisted quantification as described previously. 5 Intracytoplasmic cytokine staining In brief, splenocytes from naive or vaccinated groups of mice were incubated in the presence or absence of the E7 peptide (aa 49-57) that contains the MHC class I epitope 19 or E7 peptide (aa 30-67) that contains the MHC class II peptide. 9 Cells were stained with phycoerythrin (PE)-conjugated monoclonal rat anti-mouse CD8 or CD4 antibody (PharMingen) and subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit according to the manufacturer's instructions (PharMingen). Analysis was performed on the same number of splenocytes (1 × 10 6 ) in each flow cytometry analysis using a Becton Dickinson FACScan with CELLQuest software (Becton Dickinson Immunocytometry System).
ELISA
The anti-HPV-16 E7 antibodies in the sera were determined by a direct ELISA as described previously. 3, 5 The sera were prepared from the mice on day 14 after immunization.
